Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus-Reference-Cited by-同舟云学术

Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus

Published:2015-11-19 Issue:1 Volume:7 Page:
ISSN:1758-5996
Container-title:Diabetology & Metabolic Syndrome
language:en
Short-container-title:Diabetol Metab Syndr

Author:

Qiang Shirong,Nakatsu Yusuke,Seno Yasuyuki,Fujishiro Midori,Sakoda Hideyuki,Kushiyama Akifumi,Mori Keiichi,Matsunaga Yasuka,Yamamotoya Takeshi,Kamata Hideaki,Asano Tomoichiro

Funder

a Grant-in-Aid for Scientific Research (B) from the Ministry of Education, Science, Sports, and Culture, Japan

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1186/s13098-015-0102-8

Reference19 articles.

1. Sharma MD. Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes. Diabetes Obes Metab. 2015;17(7):616–21.

2. Hazel-Fernandez L, Xu Y, Moretz C, Meah Y, Baltz J, Lian J, Kimball E, Bouchard J. Historical cohort analysis of treatment patterns for patients with type 2 diabetes initiating metformin monotherapy. Curr Med Res Opin. 2015;31(9):1703–16.

3. Fu H, Cao D, Boye KS, Curtis B, Schuster DL, Kendall DM, Ascher-Svanum H. Early glycemic response predicts achievement of subsequent treatment targets in the treatment of type 2 diabetes: a post hoc analysis. Diabetes Ther. 2015;6(3):317–28.

4. Wang TY, Eguale T, Tamblyn R. Guidelines adherence in the treatment of patients with newly diagnosed type 2 diabetes: a historical cohort comparing the use of metformin in Quebec pre and post-Canadian Diabetes Association guidelines. BMC Health Serv Res. 2013;13:442.

5. Hayashizaki-Someya Y, Kurosaki E, Takasu T, Mitori H, Yamazaki S, Koide K, Takakura S. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. Eur J Pharmacol. 2015;754:19–24.

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of MASLD Fibrosis, FIB-4 and APRI Score in MASLD Combined with T2DM and MACCEs Receiving SGLT2 Inhibitors Treatment;International Journal of General Medicine;2024-06

2. Animal studies of sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease;Annals of Gastroenterology;2024

3. Antifibrotic effects of sodium-glucose cotransporter-2 inhibitors: A comprehensive review;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2024-01

4. Antihypertensive Effects of SGLT-2 Inhibitors and Progress in Research;Advances in Clinical Medicine;2024

5. Reversal of fibrosis and portal hypertension by Empagliflozin treatment of CCl4-induced liver fibrosis: Emphasis on gal-1/NRP-1/TGF-β and gal-1/NRP-1/VEGFR2 pathways;European Journal of Pharmacology;2023-11